SCHEMBL25384355

SCHEMBL25384355

O=C(O)Cc1csc(C2CCC(F)(F)CC2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.45
GABRA5 P31644 1/20 0.45
GABRB2 P47870 1/20 0.45
LMNA P02545 1/20 0.45
KDM4E B2RXH2 4/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
SLC6A3 Q01959 2/20 0.40
ALDH1A1 P00352 5/20 0.39
HPGD P15428 3/20 0.39
AOC3 Q16853 1/20 0.39
GAA P10253 5/20 0.38
MAPT P10636 3/20 0.37
NPC1 O15118 1/20 0.37
NFKB1 P19838 1/20 0.37
RAB9A P51151 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
F2 P00734 1/20 0.35
F2RL3 Q96RI0 1/20 0.35
EGLN1 Q9GZT9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27824215 0.87 HSD17B10 (0.54) HSD17B10GABRA5GABRB2LMNAKDM4E
SCHEMBL15348963 0.82 SLC6A3 (0.37) SLC6A3AOC3F2F2RL3DNM1L
SCHEMBL5284550 0.82 HSD17B10 (0.50) HSD17B10GABRA5GABRB2LMNAKDM4E
SCHEMBL25383120 0.82 MEN1 (0.50) LMNASMN1; SMN2ALDH1A1HPGDGAA
SCHEMBL25933572 0.71 OGA (0.42) SMN1; SMN2RAB9AF2RL3
SCHEMBL15349235 0.71 CASP3 (0.49) SMN1; SMN2ALDH1A1GAAMAPTNPC1
SCHEMBL12440438 0.70 GPR119 (0.58) HSD17B10KDM4ESMN1; SMN2HPGDGAA
SCHEMBL15725259 0.69 HSD17B10 (0.47) HSD17B10GABRA5GABRB2LMNAKDM4E
SCHEMBL28003511 0.68 F2RL3 (0.35) LMNASMN1; SMN2NPC1RAB9AF2
SCHEMBL9046241 0.67 SLC6A3 (0.47) SMN1; SMN2SLC6A3ALDH1A1AOC3DNM1L

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250064789-A1 KETOAMIDE DERIVATIVES AND PHARMACEUTICAL USES THEREOF WESTVAC BIOPHARMA CO., LTD. (CN) 2025-02-27 US disclosed
EP-4488264-A1 KETO AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF WestVac Biopharma Co., Ltd. (CN) 2025-01-08 EP disclosed
CN-116693447-B Ketone amide derivative and pharmaceutical application thereof 成都威斯克生物医药有限公司 2024-08-13 CN disclosed
WO-2023165334-A1 KETO AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF 成都威斯克生物医药有限公司 2023-09-07 WO disclosed
CN-116693447-A Ketone amide derivative and pharmaceutical application thereof 成都威斯克生物医药有限公司 2023-09-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250064789-A1 KETOAMIDE DERIVATIVES AND PHARMACEUTICAL USES THEREOF ACE2, ACE, PKD2 HSD17B10 478/4885GABRA5 1153/4885GABRB2 1621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.